Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China

Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China

Wenjuan Wang,1,* Dachuang Zhou,1,* Kejia Zhou,1 Di Zhang,1 Hao Li,1 Hongliu Zhang,1 Xin Jiang,1 Ruihua Wang,1 Xi Wang,2 Wenxi Tang1 1Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, People’s Republic of Ch...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang W, Zhou D, Zhou K, Zhang D, Li H, Zhang H, Jiang X, Wang R, Wang X, Tang W
Format: Article
Language:English
Published: Dove Medical Press 2025-05-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
HIV
Markov
Dynamic Model
Bictegravir/emtricitabine/tenofovir
China
Online Access:https://www.dovepress.com/health-economics-evaluation-of-bictegraviremtricitabinetenofovir-for-a-peer-reviewed-fulltext-article-CEOR
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.dovepress.com/health-economics-evaluation-of-bictegraviremtricitabinetenofovir-for-a-peer-reviewed-fulltext-article-CEOR

Similar Items